Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Clinical Data
Biotech
Lilly's amylin data impress with 11% weight loss, tolerability
Eli Lilly impressed analysts with results that point to the potential for the drug candidate to form part of a market-leading Zepbound combination.
Nick Paul Taylor
Jun 16, 2025 4:55am
NewAmsterdam links lipid drug to drop in Alzheimer's biomarker
Jun 9, 2025 8:25am
Metsera posts amylin data, eyes monthly GLP-1 combo
Jun 9, 2025 7:00am
RegenXBio links DMD gene therapy to improved outcomes
Jun 5, 2025 8:52am
Vigil's rare brain disease drug flunks phase 2 study
Jun 4, 2025 9:45am
J&J shares survival data on KLK2 bispecific in prostate cancer
Jun 2, 2025 6:40am